Editorial

Peripheral Arterial Disease: Increasing Awareness—A Major Step Forward

Authors: Maya J. Salameh MD, Daniel G. Federman MD

Abstract

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221–226.CriquiMH]]DenenbergJO]]LangerRD&etal;The epidemiology of peripheral arterial disease: importance of identifying the population at risk.Vasc Med19972221-2262. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384–392.FowkesFG]]HousleyE]]CawoodEH&etal;Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population.Int J Epidemiol199120384-3923. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339.CAPRIE Steering CommitteeA randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).Lancet19963481329-13394. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180–189.BhattDL]]StegPG]]OhmanEM&etal;International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.JAMA2006295180-1895. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381–386.CriquiMH]]LangerRD]]FronekA&etal;Mortality over a period of 10 years in patients with peripheral arterial disease.N Engl J Med1992326381-3866. Abbott RD, Rodriguez BL, Pretrovich H, et al. Ankle-brachial blood pressure in elderly men and the risk of stroke: the Honolulu Heart Program. J Clin Epidemiol 2001;54:973–978.AbbottRD]]RodriguezBL]]PretrovichH&etal;Ankle-brachial blood pressure in elderly men and the risk of stroke: the Honolulu Heart Program.J Clin Epidemiol200154973-9787. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:e2–e192.HirschAT]]HaskalZJ]]HertzerNR&etal;ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.J Am Coll Cardiol200647e2-e1928. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317–1324.HirschAT]]CriquiMH]]Treat-JacobsonD&etal;Peripheral arterial disease detection, awareness, and treatment in primary care.JAMA20012861317-13249. McLafferty RB, Dunnington GL, Mattos MA, et al. Factors affecting the diagnosis of peripheral vascular disease before vascular surgery referral. J Vasc Surg 2000;31:870–879.McLaffertyRB]]DunningtonGL]]MattosMA&etal;Factors affecting the diagnosis of peripheral vascular disease before vascular surgery referral.J Vasc Surg200031870-87910. McDermott MM, Mehta S, Ahn H, et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997;12:209–215.McDermottMM]]MehtaS]]AhnH&etal;Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease.J Gen Intern Med199712209-21511. Ouriel K. Peripheral arterial disease. Lancet 2001;358:1257–1264.OurielKPeripheral arterial disease.Lancet20013581257-126412. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286:1599–1606.McDermottMM]]GreenlandP]]LiuK&etal;Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment.JAMA20012861599-160613. Aslam F, Haque A, Foody J, et al. Peripheral arterial disease: current perspectives and new trends in management. South Med J 2009;102:1141–1149.AslamF]]HaqueA]]FoodyJ&etal;Peripheral arterial disease: current perspectives and new trends in management.South Med J20091021141-114914. Pearson TL, Kukulka G, Rahman ZU. Ankle brachial index measurement in primary care setting: how long does it take? South Med J 2009;102:1106–1110.PearsonTL]]KukulkaG]]RahmanZUAnkle brachial index measurement in primary care setting: how long does it take?South Med J20091021106-111015. Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107:753–756.MehlerPS]]CollJR]]EstacioR&etal;Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes.Circulation2003107753-75616. Norgren L, Hiatt WR, Dormandy JA, et al; TASC-II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC-II). J Vasc Surg 2007;45:S5–S67.NorgrenL]]HiattWR]]DormandyJA&etal;TASC-II Working GroupInter-Society Consensus for the Management of Peripheral Arterial Disease (TASC-II).J Vasc Surg200745S5-S6717. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769–1776.RadackK]]DeckCBeta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials.Arch Intern Med19911511769-177618. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.YusufS]]SleightP]]PogueJ&etal;Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N Engl J Med2000342145-15319. The ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–1559.The ONTARGET InvestigatorsYusufS]]TeoKK]]PogueJ&etal;Telmisartan, ramipril, or both in patients at high risk for vascular events.N Engl J Med20083581547-155920. Spronk S, Bosch JL, den Hoed PT, et al. Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based exercise training—randomized controlled trial. Radiology 2009;250:586–595.SpronkS]]BoschJL]]den HoedPT&etal;Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based exercise training—randomized controlled trial.Radiology2009250586-59521. Murphy TP, Hirsch AT, Ricotta JJ, et al. The claudication: exercise vs. endoluminal revascularization (CLEVER) study: rationale and methods. J Vasc Surg 2008;47:1356–1363.MurphyTP]]HirschAT]]RicottaJJ&etal;The claudication: exercise vs. endoluminal revascularization (CLEVER) study: rationale and methods.J Vasc Surg2008471356-136322. Ouriel K, McDonnell AE, Metz CE, et al. A critical evaluation of stress testing in the diagnosis of peripheral vascular disease. Surgery 1982;91:686–693.OurielK]]McDonnellAE]]MetzCE&etal;A critical evaluation of stress testing in the diagnosis of peripheral vascular disease.Surgery198291686-69323. Yao ST, Hobbs JT, Irvine WT. Ankle systolic pressure measurements in arterial disease affecting the lower extremities. Br J Surg 1969;59:676–679.YaoST]]HobbsJT]]IrvineWTAnkle systolic pressure measurements in arterial disease affecting the lower extremities.Br J Surg196959676-67924. Fowkes FG. The measurement of atherosclerotic peripheral arterial disese in epidemiologic surveys. Int J Epidemiol 1988;17:248–254.FowkesFGThe measurement of atherosclerotic peripheral arterial disese in epidemiologic surveys.Int J Epidemiol198817248-25425. United States Preventive Services Task Force. Recommendation Statement: Screening for Peripheral Arterial Disease. Washington, DC, Agency for Healthcare Research and Quality, 2005, pp 1–8.United States Preventive Services Task ForceRecommendation Statement: Screening for Peripheral Arterial Disease.Washington, DCAgency for Healthcare Research and Quality20051-826. Mohler ER III, Treat-Jacobson D, Reilly MP, et al. Utility and barriers to performance of the ankle-brachial index in primary care practice. Vasc Med 2004;9:253–260.MohlerERIII]]Treat-JacobsonD]]ReillyMP&etal;Utility and barriers to performance of the ankle-brachial index in primary care practice.Vasc Med20049253-26027. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004;110:738–743.SelvinE]]ErlingerTPPrevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000.Circulation2004110738-74328. Salameh MJ, Rundek T, Boden-Albala B, et al. Self-reported peripheral arterial disease predicts future vascular events in a community-based cohort. J Gen Intern Med 2008;23:1423–1428.SalamehMJ]]RundekT]]Boden-AlbalaB&etal;Self-reported peripheral arterial disease predicts future vascular events in a community-based cohort.J Gen Intern Med2008231423-1428